Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Goldman Sachs Group Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while Goldman Sachs Group Inc trades at $887.59 (market cap $258.33B). The key difference: Goldman Sachs Group Inc is far larger — about 54.8× Definium Therapeutics Inc. Common Shares's market cap, and Goldman Sachs Group Inc pays a 2.25% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Goldman Sachs Group Inc for 101 Days on average.
| DFTX | GS | |
|---|---|---|
Market Cap | $4.71B | $258.33B |
Volume | 1,966,636 | 2,388,334 |
Sector | Health | Financials |
52-Week High | $48.45 | $1.15K |
52-Week Low | $10.68 | $744.60 |
Typical Hold Time | 0 Days | 101 Days |
Enterprise Value | $3.67B | $816.34B |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Goldman Sachs (GS) trades at $882.59, down 1.63% with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $20.98 versus $14.47 expected. Revenue growth accelerated to $58.28B in 2025 with net income margin improving to 31.68%. Recent news highlights the company's focus on expanding to a $70B revenue base and AI initiatives.
The outlook remains positive with analyst consensus target of $1,130 representing 28% upside potential. Key risks include volatile cash flows with negative operating cash of -$45.15B in 2025 and potential FICC business softness. The current valuation at P/E of 13.7 appears attractive relative to earnings growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
